Amlodipine/candesartan cilexetil - HanAll BioPharma

Drug Profile

Amlodipine/candesartan cilexetil - HanAll BioPharma

Alternative Names: Amlodipine/candesartan; Candesartan cilexetil/amlodipine - HanAll BioPharma; HL-068

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HanAll Biopharma
  • Class Antihypertensives; Benzimidazoles; Biphenyl compounds; Dihydropyridines; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension

Most Recent Events

  • 08 Dec 2016 HanAll BioPharma plans a phase I bioequivalence trial in Healthy volunteers in South Korea (PO) (NCT02988362)
  • 13 Aug 2015 HanAll has patent protection for amlodipine/candesartan cilexeti
  • 13 Aug 2015 Phase-III clinical trials in Hypertension in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top